AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02159547 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 50 ml normal saline
Study NCT00200226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: misoprostol 400mcg 12 hrs prior to procedure
Study NCT00200226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin B6
Description: Vitamin B6 50 mg orally 12 hrs prior to procedure
Study NCT01816464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.~The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe.
Study NCT01947400 — intervention group
Intervention type: OTHER
Intervention: Hospitalists
Description: AIDET Training
Study NCT04054037 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observation study, no intervention will be indicated during diagnosis and treatment.
Study NCT02674412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Study NCT02674412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
Study NCT00698269 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00698269 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00698269 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT03535220 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Protease Inhibitors
Description: Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents
Study NCT02376192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Initial MicroScan® (Microvision Medical) SDF Measurement
Description: Initial SDF measurements are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia.
Study NCT02376192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia- Bupivacaine
Description: The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
Study NCT02376192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparative MicroScan® (Microvision Medical) SDF Measurement
Description: A second comparative SDF measurement be recorded within 10 minutes after induction of spinal anesthesia.
Study NCT02376192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus Phenylephrine/Ephedrine Treatment
Description: Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
Study NCT02376192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Infusion
Description: Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
Study NCT00876473 — intervention group
Intervention type: PROCEDURE
Intervention: CPAP system
Description: Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange~CPAP systems:~Continuous high-flow CPAP with fixed value PEEP valve~Continuous high-flow CPAP with Boussignac valve~Demand flow CPAP supplied by ventilator
Study NCT01320683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01320683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01320683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT03466502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Description: Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence
Study NCT03789552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T89 capsule
Description: T89 capsules (75mg)
Study NCT03789552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsules (0mg)
Study NCT03789552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsules (0mg)
Study NCT00712088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ICARE
Description: Group-level intervention (Project ICARE)
Study NCT00712088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HCT
Description: Offer of HIV counseling and testing
Study NCT03801616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality in controlling pain
Study NCT00847496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AWBAT
Description: One-time application of dressing over partial-thickness burns
Study NCT00847496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biobrane
Description: One-time application over partial-thickness burns
Study NCT04508569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Big Decisions
Description: Big Decisions is a promising teen pregnancy prevention intervention that consists primarily of abstinence-plus sexual health education curriculum. The intended dosage for students is 10 classroom-based sexual health lessons.
Study NCT04508569 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Big Decisions
Description: Big Decisions is a promising teen pregnancy prevention intervention that consists primarily of abstinence-plus sexual health education curriculum. The intended dosage for students is 10 classroom-based sexual health lessons.
Study NCT01921829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protocolized Diuretic Strategy
Description: The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide).
Study NCT04385602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intratracheal dexmedetomidine
Description: Thirty minutes before the end of the surgery, Dex (0.5μg/kg diluted and mixed in 1ml saline in a medical spray bottle) will be sprayed down the intratracheal tube
Study NCT04385602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Thirty minutes before the end of the surgery, 1ml saline in a medical spray bottle will be sprayed down the intratracheal tube
Study NCT01200693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus eluting stent
Description: Implantation of Zotarolimus eluting stent
Study NCT04355078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: Muscular and neural training by complex exercises
Study NCT04355078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: Strength Training
Study NCT02353182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Loading dose:1 mcg/kg over 10 minutes. Infusion: Start 1-1.5 mcg/kg/hr. Titrate up or down within 50% of starting doses as needed.
Study NCT02353182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2-0.5 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed.
Study NCT02353182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Administered in caudal/epidural/field block: 0.175%-0.25% (dose at discretion of anaesthetist)
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: Oral capsules
Study NCT01320683 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
Description: Given IV
Study NCT01320683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01320683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01320683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo
Description: Oral capsules
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Oral tablets
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Oral tablets
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Oral tablets
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Oral tablets
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Oral tablets
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Oral tablets
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Oral capsules
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Oral capsules
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine
Description: Oral tablets
Study NCT04476030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Description: Oral tablets
Study NCT02040662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Thoracic Epidural Block
Description: Before anesthesia, continuous thoracic epidural block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (air). A catheter is advanced ca. 3-5 cm, and test dose with 2 ml of lidocaine 2% i injected. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 6 ml bolus is injected, followed by an infusion of the same mixture at 0,06 ml/kg/h for postoperative pain management.
Study NCT02040662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Thoracic Paravertebral Block
Description: Before anesthesia, continuous thoracic paravertebral block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (normal saline). After injection of 5-10 ml of normal saline a catheter is advanced medially ca. 5 cm. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 20 ml bolus is injected, followed by an infusion of the same mixture at 0,08 ml/kg/h for postoperative pain management
Study NCT02040662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia with Morphine
Description: Once arrived at the PACU all patients are placed on a postoperative analgesia regimen, that include:~* patient-controlled analgesia with morphine (bolus dose 2 mg, lockout time 10 min)~* paracetamol 1000 mg iv every 8 hrs~* ketoprofen 100 mg iv every 12 hrs
Study NCT01410734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Description: 2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
Study NCT03228810 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: (2) 10 mL tubes will be collected
Study NCT03228810 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue biopsy
Description: Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy
Study NCT00394030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK716155 subcutaneous injections
Description: GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
Study NCT03391973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
Study NCT05369910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light exposure (Flash)
Description: Light exposure (Flash) is administered for one hour on 7 consecutive days. During the light exposure, participants are seated 120 cm in front of a white curtain that is illuminated by an LED light source (Dawe stroboscope type 1214B, 5 Hz).
Study NCT05369910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light deprivation (Dark)
Description: Light deprivation (Dark) is administered for one hour on 7 consecutive days. During the Dark intervention, participants are seated in a room in complete darkness.
Study NCT02992808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant gonadotropins
Study NCT02992808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HP-HMG
Study NCT00326625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg glatiramer acetate
Description: parenteral drug
Study NCT00326625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02353182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Administered in caudal/epidural/field block: 0.2% (dose at discretion of anaesthetist)
Study NCT01417793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Program
Description: Comparison of smoking cessation rate among different smoking cessation program
Study NCT02047474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT02047474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01276314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti- TNF-a
Description: 25mg BIW, SC
Study NCT01276314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 1-1.5 mg / kg / day
Study NCT03843684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed foot orthoses
Description: 3D printed foot orthoses with arch support
Study NCT03843684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5 degrees lateral wedge insoles
Description: Insoles with a lateral inclination set at 5 degrees
Study NCT02677090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (including Maltodextrin)
Study NCT02677090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose 1 - Promitor®
Study NCT02677090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose 2 - Promitor®
Study NCT02677090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose 3 - Promitor®
Study NCT01860261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and Strength Training Intervention
Description: The exercise intervention has three components: (1) aerobic exercise with a metabolic equivalent of task (MET) energy expenditure of at least 900 MET-minutes per week; (2) strength training consisting of 2 sets of 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 sets of 3 leg exercises (leg press, extension, and flexion) and 2 sets each of abdominal crunches and back extensions. Weights for each exercise will be gradually increased as participants can complete 12 repetitions for each set on 2 consecutive sessions, with participants performing strength training twice per week total. Three workshops on using ChiWalking or ChiRunning technique for achievement of aerobic activity goals will be provided to participants in the experimental arm.
Study NCT00514410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
Study NCT00514410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken once a day for three months
Study NCT00240071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
Study NCT00240071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Description: aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)
Study NCT04261270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC09F+Oseltamivir
Description: ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
Study NCT04261270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir+Oseltamivir
Description: Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
Study NCT04261270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 75mg ,once a day
Study NCT02611258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil 20 mg to be taken orally once daily, for 3 months
Study NCT02240381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: During OGTT 75gm of glucose will be given followed by phlebotomy
Study NCT02240381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
Study NCT02240381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00028756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00028756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00028756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00028756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00028756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine sulfate
Description: Given IV
Study NCT01655810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Multivitamin containing cholecalciferol 4000 units orally daily
Study NCT01655810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Multivitamin containing cholecalciferol 600 units orally daily
Study NCT01655810 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: 500 mg orally twice daily
Study NCT02550509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound echogenicity
Description: ultrasound echogenicity to patient with stroke
Study NCT02550509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: elastography
Description: elastography to patient with stoke
Study NCT01826201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOL4239
Description: 10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
Study NCT01826201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days